TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06282861
Drug: Striverdi
Normalized name: Striverdi
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Beglan
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Betamican
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Inaspir
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Soltel
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Eklira
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Bretaris
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Seebri
Normalized name: Seebri
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Tovanor
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Enurev
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Tavulus
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Braltus
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Gregal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Incruse
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06282861
Drug: Rolufta
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per product specifications
Study: NCT06495892
Drug: Diuretic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic therapy will be tailored according to peripheral venous pressure targets or standard approach
Study: NCT05362292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo pill
Study: NCT05171166
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin,leucovorin, and 5-FU
Study: NCT05171166
Drug: cTACE or DEB-TACE
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: lipiodol or microspheres that mixed with EPI
Study: NCT04792190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take 1 blinded capsule of placebo drug dosed once daily
Study: NCT06337981
Drug: (AJU-S56 5% and placebo)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (AJU-S56 5%) and placebo(Vehicle), 1drop/1times, 3times in a day
Study: NCT06337981
Drug: AJU-S56 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: (AJU-S56 5%), 1drop/1times, 6times in a day
Study: NCT06337981
Drug: Placebo(Vehicle)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo(Vehicle), 1drop/1times, 6times in a day
Study: NCT05292001
Drug: Iron-Dextran Complex Injection [InFed]
Normalized name: iron-dextran complex Injection [InFed]
Approvals — FDA: no, EMA: no, PMDA: no
Description: single 1000mg dose
Study: NCT05962255
Drug: Continous intravenous infusion of 5% Glucose solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 48h infusion of 5% Glucose at a fixed rate v= 83 ml/h x 24h = 2l/24h
Study: NCT04848402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT03814135
Drug: Hipnos 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet, oral, once a day.
Study: NCT03814135
Drug: Hipnos 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet, oral, once a day.
Study: NCT06717464
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250mg/m2, D1-D14, q3w, for 24 weeks (8 cycles)
Study: NCT06114719
Drug: Silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects of the experimental group will receive silymarin (capsules containing 100 mg silymarin, expressed as silibinin) three days preoperatively. The dose they receive will be the recommended dose for the registered indications (400 mg daily, orally, divided into two doses).
Study: NCT05393245
Drug: Long-acting muscarinic antagonists (LAMAs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting muscarinic antagonists (LAMAs)
Study: NCT05393245
Drug: Long-acting β2-agonists (LABAs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting β2-agonists (LABAs)
Study: NCT05373212
Drug: Euglycemic clamp with BC Combo THDB0207
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
Study: NCT05373212
Drug: Euglycemic clamp with Humalog® Mix25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure.
Study: NCT04753489
Drug: Xarelto® film-coated tablet 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xarelto® is manufactured by Bayer AG, Germany. Each tablet contains 10 mg of rivaroxaban.
Study: NCT05833711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC Weekly Injection
Study: NCT04418895
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: possible consolidative neo-adjuvant chemotherapy. This treatment is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist.
Study: NCT04418895
Drug: CAPOX
Normalized name: Capecitabine and Oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: possible consolidative neo-adjuvant chemotherapy. This treatment is at the discretion of the treating medical oncologist, radiation oncologist, and surgical oncologist.
Study: NCT05200312
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study: NCT05200312
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study: NCT04924621
Drug: Sufentani(T group)
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 0.02-0.05ug/kg, intravenous injection
Study: NCT04924621
Drug: Drug use target(T group)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Make BIS \< 60 .
Study: NCT04924621
Drug: Sufentanil(C group)
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil 5ug, intravenous injection
Study: NCT04924621
Drug: Drug use target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Make the BIS between 70 and 80.
Study: NCT05073939
Drug: Oral Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo orally
Study: NCT06003777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as oral suspensions as escalating single doses to be determined.
Study: NCT05229809
Drug: Yiqi Wenyang Jiedu prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
Study: NCT05229809
Drug: Simulation agent of Yiqi Wenyang Jiedu prescription
Normalized name: Combinations of antineoplastic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
Study: NCT05701553
Drug: Anti-PD-1/PD-L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection at indicated dose for at least 6 months
Study: NCT05701553
Drug: S-Adenosyl-Methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally at indicated dose for at least 6 months
Study: NCT00893854
Drug: Diclophenac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05480228
Drug: NRD135SE.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: The double-blind treatment phase is up to 13 weeks.
Study: NCT05195203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple dose(s) of placebo
Study: NCT05881707
Drug: CKD-828, D064, D702
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT04883255
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day course of orally-administered placebo
Study: NCT05922930
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by IV (vein)
Study: NCT06011265
Drug: Myrbetriq 25Mg Extended-Release Tablet
Normalized name: Myrbetriq 25mg Extended-Release Tablet (Once-Daily)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants take 4x 25mg Myrbetriq 25Mg Extended-Release Tablet orally.
Study: NCT06011265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants take empty capsule orally
Study: NCT06006871
Drug: Usual treatment for ADHD
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients continue with their stable pharmacological treatment and do not receive any additional cognitive intervention.
Study: NCT05095298
Drug: Vaccine, COVID19
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is a prospective open-labeled study, We intended to recruit the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before, and volunteered to receive the third dose of vaccine (inactivated vaccine, recombinant subunit protein vaccine or mRNA vaccine) into the experimental group, and the participants who completed 2 doses of inactivated COVID-19 vaccine 4-8 months before without a third dose of vaccination plan into the control group. Participants in the experimental group received the third dose of SARS-CoV-2 vaccination at baseline, and participants in the control group received no intervention. Each subject will be followed up for one year after enrollment, and neutralizing antibodies and total antibodies will be tested at the specified time points, as well as the records of adverse events and adverse reactions.
Study: NCT05304442
Drug: Ferric Derisomaltose 1000 Mg in 10 mL INTRAVENOUS SOLUTION [Monoferric]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Dose of IV Iron
Study: NCT05304442
Drug: Ferrous Sulfate 65 mg elemental iron (325 mg tablets)
Normalized name: ferrous sulfate
DrugBank: Ferrous succinate (DB14489)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily by mouth for 42 days
Study: NCT06049147
Drug: MBF-015 4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBF-015 oral capsules Histone deacetylase inhibitor
Study: NCT06049147
Drug: MBF-015 16 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBF-015 oral capsules Histone deacetylase inhibitor
Study: NCT06049147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard gelatin capsules filled with cellulose microcrystalline
Study: NCT05689879
Drug: STOP arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-alpha antagonists withdrawal
Study: NCT06101368
Drug: Medication
Normalized name: Acne Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug will maintain their usual activity level, foot care, diet, and blood glucose diary on a regular basis. Continue the prescribed medication
Study: NCT05857566
Drug: RDX-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: A potent, selective, and gut-specific microsomal triglyceride transfer protein (MTP) inhibitor.
Study: NCT05221008
Drug: SHR6508；Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A:SHR6508 low dose
Study: NCT05221008
Drug: SHR6508；Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B:SHR6508 medium dose
Study: NCT05221008
Drug: SHR6508；Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C:SHR6508 high dose
Study: NCT05221008
Drug: SHR6508；Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D:SHR6508 high dose(single dose)
Study: NCT05160363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be administered in combination with pyronaridine tetraphosphate (8 patients), OR, in combination with piperaquine tetraphosphate (8 patients), OR, only matched placebo tablets will be administered (8 patients)
Study: NCT05575700
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg tablet three times daily
Study: NCT05575700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet three times daily
Study: NCT05866692
Drug: TY-2699a
Approvals — FDA: no, EMA: no, PMDA: no
Description: TY-2699a PO, BID~Escalation stage: increased dose cohorts from low dose to MTD~Expansion stage: The dose for the Expansion stage will be determined based on results
Study: NCT00389753
Drug: Application of Aruba Aloë formula F-BC-096 or control
Normalized name: BC Original Formula
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06302465
Drug: narlumosbartmab plus doxorubicin、cisplatin、methotrexate、ifosfamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narlumosbartmab is combined with neoadjuvant chemotherapy at 120mg i.h. in day 1, 8, 15, 28 and every 28 days after that.
Study: NCT06302465
Drug: doxorubicin、cisplatin、methotrexate、ifosfamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxorubicin(37.5mg/m\^2/d)、cisplatin(120mg/m\^2/d)、methotrexate(8-12g/m\^2/d)、ifosfamide(2.4g/m\^2/d)
Study: NCT04316559
Drug: TRV734
Approvals — FDA: no, EMA: no, PMDA: no
Description: biased agonist at mu opioid receptors
Study: NCT04992468
Drug: Ovulation triggering with GnRH-a+rhCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant follicle stimulating hormone (rFSH) 225-300 IU (Gonal-F®/Puregon®/ Ovaleap®/Rekovelle®) Micronized progesterone 200mg (Utrogestan®) Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®) + Recombinant human chorionic gonadotropin (rhCG) 250μg (Ovitrelle®)
Study: NCT06393803
Drug: 2mg KH607 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receive KH607 tablets or placebo orally single dose.
Study: NCT06393803
Drug: 5mg KH607 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receive KH607 tablets or placebo orally single dose.
Study: NCT06393803
Drug: 10mg KH607 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receive KH607 tablets or placebo orally single dose or multiple doses.
Study: NCT06393803
Drug: 20mg KH607 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receive KH607 tablets or placebo orally single dose or multiple doses.
Study: NCT06393803
Drug: 30mg KH607 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receive KH607 tablets or placebo orally single dose or multiple doses.
Study: NCT06393803
Drug: 40mg KH607 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receive KH607 tablets or placebo orally single dose.
Study: NCT06393803
Drug: 50mg KH607 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receive KH607 tablets or placebo orally single dose.
Study: NCT06393803
Drug: 60mg KH607 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject receive KH607 tablets or placebo orally single dose.
Study: NCT03678545
Drug: Placebo (blinded)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is matched to the active drug (dupilumab), and is given in the same manner: a subcutaneous injection every two weeks for a total of 6 injections.
Study: NCT06307847
Drug: SP5M001 inj
Approvals — FDA: no, EMA: no, PMDA: no
Description: pre-filled syringe
Study: NCT06307847
Drug: Synovian inj
Approvals — FDA: no, EMA: no, PMDA: no
Description: pre-filled syringe
Study: NCT05501639
Drug: long-acting β2-agonists (LABA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: long-acting β2-agonists (LABA)
Study: NCT05501639
Drug: inhaled corticosteroids (ICS)
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhaled corticosteroids (ICS)
Study: NCT05269459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching gel caps containing no active drug. Subjects will take 4 capsules twice daily.
Study: NCT04861779
Drug: HSK29116
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HSK29116
Study: NCT04794738
Drug: SHR8554
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR8554 Injection; high dose
Study: NCT04794738
Drug: SHR8554
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR8554 Injection; low dose
Study: NCT04907253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice daily
Study: NCT02065323
Drug: Standard ADT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard androgen deprivation therapy with either continually dosed LHRH agonist or antagonist, or achieved via bilateral orchiectomy.
Study: NCT05290662
Drug: oNKord®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
Study: NCT05290662
Drug: Cyclophosphamide/Fludarabine (Cy/Flu)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepleting conditioning regimen
Study: NCT06178367
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle ingredients including aqua, paraffinum liquidum, glycerin, petrolatum, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, arachidyl alcohol, squalane, behenyl alcohol, phenoxyethanol, arachidyl glucoside, allantoin, chlorphenesin, and disodium EDTA
Study: NCT06289946
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: We will apply placebo moisturizing cream to the wrist
Study: NCT05296317
Drug: Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Arm 1: 2 cycles of chemotherapy with administration of G-CSF (filgrastim or lenograstim) on D2, D4 to D7 or D8..~Realization of blood sampling at D1, D4, D8 and D14
Study: NCT05296317
Drug: Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Arm 2: 2 cycles of chemotherapy with administration of peg-G-CSF (pegfilgrastim) on D2.~Realization of blood sampling at D1, D4, D8 and D14
Study: NCT04888806
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment plan for mCRC, determined by the investigator
Study: NCT04877678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical looking placebo, twice a day
Study: NCT04601116
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 tablet per day for 2 years
Study: NCT05573698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo will be administered by intravenous (IV) injection
Study: NCT05007548
Drug: Ga68-Dolacga Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ga68-Dolacga Injection, 2.0±1.0 mCi, single dose, iv bolus
Study: NCT05698394
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml normal saline will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth.
Study: NCT06704100
Drug: Fosamprenavir Calcium & Sodium Alginate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1400 mg FOS-SA BID: 15 ml oral solution containing 1400 mg fosamprenavir calcium and 24.5 mg sodium alginate administered BID
Study: NCT06719310
Drug: ACC017+FTC/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACC017+FTC/TAF
Study: NCT06719310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06716905
Drug: ACT500 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single ascending oral dose of ACT500 Tablets under fasting state on the first day in Part 1
Study: NCT06716905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matched to ACT500 Tablets.
Study: NCT06716905
Drug: ACT500 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive multiple ascending oral dose of ACT500 Tablets under fasting state once daily for 7 days in Part 2.
Study: NCT06716918
Drug: Corticosteroid Injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who have received antenatal corticosteroids (betamethasone or dexamethasone) prior to cesarean section as part of their prenatal care.
Study: NCT06715839
Drug: [68Ga]Ga-DOTA-H2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\[68Ga\]Ga-DOTA-H2D3). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-DOTA-H2D3 injection.
Study: NCT06715839
Drug: [18F]F-RESCA-RB14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi/kg of a HER2-targeted probe (\[18F\]F-RESCA-RB14). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RB14 injection.
Study: NCT06715839
Drug: [68Ga]Ga-NOTA-T4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients (especially those with gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\[68Ga\]Ga-NOTA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-T4 injection.
Study: NCT06715839
Drug: [18F]F-RESCA-T4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients (especially those with gastric cancer/pancreatic cancer) will receive 0.05-0.1 mCi/kg of a Trop2-targeted probe (\[18F\]F-RESCA-T4). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-T4 injection.
Study: NCT06715839
Drug: [68Ga]Ga-NOTA-G5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\[68Ga\]Ga-NOTA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-G5 injection.
Study: NCT06715839
Drug: [18F]F-RESCA-G5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi/kg of a GPC3-targeted probe (\[18F\]F-RESCA-G5). ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-G5 injection.